The brief

Analyst view

• Pfizer's major portfolios include vaccines (Comirnaty COVID-19, Paxlovid), primary care and oncology.
• Acquired Metsera for $10 billion in November 2025 for four differentiated clinical-stage GLP-1 and amylin programs.
• MET-097i is a monthly injectable GLP-1 showing 12.3% weight loss in Phase 2b; Phase 3 planned for late 2025.

Technical approach

As reported

Monthly GLP-1

Long-acting GLP-1 receptor agonist

MET-097i is engineered for once-monthly dosing, aiming to improve convenience and compliance versus weekly competitors like Wegovy.

Dual agonists

GLP-1 and amylin combinations

Metsera's pipeline includes amylin analog candidates (MET-233i) that can be combined with GLP-1s, potentially enhancing weight loss and tolerability.

Multiple routes

Injectable and oral formulations

Metsera developed both parenteral and oral candidates, offering patients options and reducing injection burden if oral versions succeed.